l carnitine and ssri Frontiers The Role of L-Carnitine in

389 In contrast, for patients with nonresectable, advanced, or metastatic ESCC, the POWER trial, a phase III study of cisplatin and 5-fluorouracil with or without the monoclonal antibody panitumumab, was stopped early owing to a lack of efficacy in the panitumumab arm, indicating that EGFR inhibition with panitumumab did not improve survival in this unselected advanced ESCC population

[1] Persistently high B12 levels warrant medical investigation, as they may signal liver disease, kidney dysfunction, or certain haematological disorders

Awasthi YC, Yang Y, Tiwari NK, Patrick B, Sharma A, Li J et al

C.VidalJ

Use in children under the guidance of a relevant healthcare provider

& Al-Tameemi, I